Background
==========

Non-traumatic, spontaneous subarachnoid hemorrhage (SAH) affects 16,000 to 17,000 individuals each year in the United States \[[@B1]-[@B3]\]. SAH has a 30-day mortality rate exceeding 40%, and surviving patients often demonstrate significant morbidity \[[@B2],[@B4]\]. Over 80% of SAH can be attributed to intracranial aneurysm (IA) rupture. Familial aggregation studies of SAH have consistently identified an increased risk of a first-degree relative with SAH or family history of SAH independent of smoking and hypertension \[[@B5]\].

Variants of the apolipoprotein E (*APOE*) gene have been associated with Alzheimer\'s disease, lipid disorders and cardiovascular disease \[[@B6]-[@B8]\]. Previous studies have demonstrated that *APOE*ε4 and/or *APOE*ε2 are associated with lobar intracerebral hemorrhage (ICH) \[[@B9],[@B10]\]. We recently reported that haplotypes which include polymorphisms in the 5\' untranslated region of the *APOE*gene are risk factors for lobar ICH \[[@B11]\]. Specific to SAH, Kokubo *et al*. \[[@B12]\] found significant association of *APOE*ε4 with SAH in a Japanese population. Niskakangas *et al*. \[[@B13]\] reported association of *APOE*ε4 with adverse outcome after aneurysmal SAH. No study on other polymorphisms of *APOE*with regard to risk of SAH has yet been reported.

In addition to *APOE*, the elastin (*ELN*) gene emerged as a putative gene for IA after linkage was found on 7q11, where *ELN*is located \[[@B14]\]. However, prior association studies of SNPs in *ELN*have been contradictory and remain inconclusive \[[@B15],[@B16]\]. Further, few studies have been performed in US populations.

We performed a case-control study examining the association of variants in *APOE*and *ELN*among a group of US Caucasians with SAH.

Methods
=======

Subjects
--------

The methodology of the *Genetic and Environmental Risk Factors of Hemorrhagic Stroke*study have been previously reported \[[@B5],[@B11]\]. Cases of potential ICH or SAH in the Greater Cincinnati and Northern Kentucky are identified by surveillance of 16 hospital emergency and radiology departments and through monitoring of hospital discharge diagnoses. Eligible cases are ≥ 18 years, are without trauma or brain tumor as the cause of hemorrhage, and reside within a 50-mile radius of the University of Cincinnati. A subset of cases was invited to enroll in a direct interview and genetic sampling arm of the study. The response rate was reasonable with over 60% of the cases agreeing to participate. Two controls for each interviewed case, matched by age (± 5 years), race, and gender were recruited from the general population through random digit dialing. Controls were informed of their participation in a risk factor study. Institutional Review Boards at each hospital approved the study, and informed consents were obtained from the participants.

SAH was defined as non-traumatic abrupt onset of severe headache or altered level of consciousness associated with blood in the subarachnoid space on CT or at autopsy, or with a clinical history and examination consistent with SAH where xanthochromia and increased red blood cells are found in the cerebrospinal fluid.

A total of 309 Caucasians were included for analysis, of which 107 were SAH cases matched to 202 controls. There was no significant difference in the average age of cases and controls (51.48 ± 12.93 yrs vs. 50.68 ± 12.23 yrs; *p*= 0.521) or gender distribution (64.4% vs. 64.8% female; *p*= 0.992) between the cases and the controls. We also genotyped samples from a small group of African American subjects. However, the limited sample size (24 cases and 43 matched controls) lacked sufficient power to identify associations. Thus, our results refer only to Caucasian cases and controls.

DNA analysis
------------

Buccal swabs were collected from each participant at the time of interview, and DNA was extracted by standard methods. Genotyping for *APOE*ε2/ε3/ε4 alleles was performed by RFLP \[[@B17]\]. For analysis of the SNP markers, genomic DNA was preamplified by whole genome amplification (WGA) using improved-primer extension preamplification. The WGA kit (High-Fidelity Expand Template System) was obtained from Roche Pharmaceuticals. Five nanograms of DNA was subjected to WGA and then diluted 50-fold, of which 2 μl was used for SNP genotyping. The WGA protocols are validated for analysis of genetic markers in our laboratory \[[@B18]\].

The TaqMan™ (fluorogenic 5\' nuclease) assay was used for SNP genotyping. The primers and probes were obtained from Applied Biosystems. PCR was conducted in ABI 9700 thermocyclers, and the end-point results scored using the ABI 7900HT Sequence Detection System. In each 384-well plate, two reference samples and two negative controls were included for quality control.

We analyzed 12 SNPs spanning a 16 kb fragment on the *APOE*gene (Table [1](#T1){ref-type="table"}) of which five upstream markers are now assigned locations on the *TOMM40*gene \[[@B19]\]. Physical distance between the most distal 3\'SNP (*rs10119*) on *TOMM40*and the most proximal 5\'SNP (*rs769446*) on *APOE*is approximately 2 kb. These 12 SNPs were analyzed in our previous study on ICH, which showed haplotypic association with lobar ICH \[[@B11]\]. We selected 10 SNPs on the *ELN*gene (Table [2](#T2){ref-type="table"}), which were reported in previous association studies involving aneurysmal SAH \[[@B14]-[@B16]\].

###### 

Distribution of the studied SNPs in the *APOE*gene region

  **SNP No.**   **dbSNP ID (\*)**   **NCBI Location**   **Genomic Location**
  ------------- ------------------- ------------------- ----------------------
  SNP1          *rs157581*(TC)      17663932            *TOMM40*EX2
  SNP2          *rs1160983*(GA)     17665447            *TOMM40*EX5
  SNP3          *rs1160985*(TC)     17671630            *TOMM40*IN5
  SNP4          *rs1160984*(CT)     17672142            *TOMM40*IN5
  SNP5          *rs10119*(GA)       17674891            *TOMM40*3\'UTR
  SNP6          *rs769446*(AT)      17676846            *APOE*Promoter
  SNP7          *rs405509*(TC)      17677054            *APOE*Promoter
  SNP8          *rs440446*(CG)      17677385            *APOE*5\'UTR
  SNP9          *rs769452*(CT)      17679328            *APOE*EX2
  SNP10         *rs429358*(TC)      17680159            *APOE*EX4
  SNP11         *rs769455*(TC)      17680258            *APOE*EX4
  SNP12         *rs7412*(CT)        17680297            *APOE*EX4

###### 

Distribution of the studied SNPs in the *ELN*gene

  **SNP No.**   **dbSNP ID (\*)**   **NCBI Location**   **Genomic Location**
  ------------- ------------------- ------------------- ----------------------
  SNP1          *rs3757584*(GT)     11474039            5\' UTR
  SNP2          *rs868005*(AG)      11478458            IN1
  SNP3          *rs2301995*(CT)     11485484            IN4
  SNP4          *rs2301994*(CT)     11485607            IN4
  SNP5          *rs3801459*(AC)     11487753            IN4
  SNP6          *rs13229379*(AC)    11489504            IN5
  SNP7          *rs2239691*(GA)     11502513            IN19
  SNP8          *rs2071307*(CT)     11504058            EX20
  SNP9          *rs104272300*(GA)   11507178            IN22
  SNP10         *rs3757587*(CT)     11514372            IN31

(\*) In Tables 1 and 2, the second nucleotide position under dbSNP ID represents the minor allele.

Statistical methods
-------------------

Allele frequencies were estimated by gene counting. Conformity of genotype proportions to Hardy-Weinberg equilibrium (HWE) was tested by a goodness-of-fit χ^2^test. Haplotype frequencies and probabilities of haplotype pairs for each individual were estimated by PHASE version 2.1. PHASE implements Bayesian methods for estimating haplotypes from population data \[[@B20]\]. Allele and genotype frequency differences were tested using allelic and genotypic χ^2^tests, respectively. Haplotype associations were tested using χ^2^and haplotype trend regression (HTR) \[[@B21]\]. All *p*-values for allele, genotype and haplotype associations were empirically determined by Monte Carlo simulations as described by Becker and colleagues \[[@B22],[@B23]\]. Multiple testing was accounted for by testing a global hypothesis of no association for each of the single locus and haplotype test \[[@B22],[@B23]\].

Genomic control
---------------

We performed a genomic control analysis to adjust for population substructure \[[@B24]\]. This was done by typing 30 unlinked SNPs distributed throughout the genome as null markers in all samples (cases and controls) and conducting test statistics to estimate λ following the methods as described \[[@B25]\].

Results
=======

Genetic variation at the *APOE*locus
------------------------------------

Genotype and allele frequencies among the cases and the controls are presented in Table [3](#T3){ref-type="table"}. Genotypes at all 12 markers were in HWE. We did not observe significant association either at allelic or genotypic level (global *p*= 0.452 and 0.807, respectively). Marginal frequency differences between cases and controls at allelic and genotype levels were observed in SNP 1 and 4 (Table [3](#T3){ref-type="table"}). We performed a separate analysis for the isoformic ε2/ε3/ε4 alleles, which also revealed no significant association (Table [4](#T4){ref-type="table"}).

###### 

Distribution of genotypes and allele frequencies at the *APOE*gene in the Caucasian cases and controls

  **Locus**   **Genotype**   **Freq(q)**   **Cases vs. Controls (*p*-value)**                   
  ----------- -------------- ------------- ------------------------------------ ------- ------- -------
  SNP1        70             32            1                                    0.165   0.056   0.142
              107            71            7                                    0.230           
  SNP2        102            4             0                                    0.019   0.371   0.641
              184            11            1                                    0.033           
  SNP3        23             53            25                                   0.490   0.518   0.738
              41             93            55                                   0.463           
  SNP4        95             7             0                                    0.034   0.062   0.144
              162            22            3                                    0.075           
  SNP5        55             41            5                                    0.252   0.570   0.589
              91             66            14                                   0.275           
  SNP6        74             27            2                                    0.150   0.164   0.327
              124            69            4                                    0.195           
  SNP7        81             19            0                                    0.095   0.536   0.503
              145            35            3                                    0.112           
  SNP8        45             50            10                                   0.333   0.304   0.548
              75             95            26                                   0.375           
  SNP9        104            1             0                                    0.005   0.289   0.760
              185            3             1                                    0.013           
  SNP10       71             21            2                                    0.133   0.361   0.675
              130            48            6                                    0.163           
  SNP11       105            0             0                                    \-      0.145   0.145
              194            5             0                                    0.013           
  SNP12       83             11            0                                    0.059   0.108   0.213
              149            34            1                                    0.098           
  Global                                                                                0.452   0.807

Note: In Tables 3 and 6, Genotype \'aa\' represents the minor homozygous genotype; the first row corresponding to each SNP marker presents the data on cases and the second row presents the data on controls.

###### 

Distribution of APOE ε2/ε3/ε4 alleles and genotypes

                 **Case (freq)**   **Control (freq)**   ***P***
  -------------- ----------------- -------------------- ---------
  **Genotype**                                          
  ε2/ε2          0                 1 (0.005)            0.998
  ε2/ε3          10 (0.106)        32 (0.174)           0.162
  ε2/ε4          1 (0.011)         2 (0.011)            0.997
  ε3/ε3          61 (0.649)        97 (0.527)           0.069
  ε3/ε4          20 (0.213)        46 (0.250)           0.557
  ε4/ε4          2 (0.021)         6 (0.033)            0.727
  **Allele**                                            
  ε2             11 (0.058)        36 (0.098)           0.143
  ε3             152 (0.808)       272 (0.740)          0.073
  ε4             25 (0.132)        52 (0.163)           0.386

We conducted an analysis to test for association at the haplotype level based on data from all 12 SNPs (Table [5](#T5){ref-type="table"}). Using PHASE, we observed a total of 66 haplotypes. In Table [5](#T5){ref-type="table"}, we present data on 9 common haplotypes (frequency \>0.02 in either cases or controls as inferred by PHASE. TGTCGATCCTTC (Hap1) was inferred as the most common haplotype, which accounted for 30% and 19% of all haplotypes in cases and controls, respectively. Global tests of association were significant for both χ^2^test and HTR (*p*= 0.019 and 0.036, respectively). Among all haplotypes, Hap1 showed significant difference between cases and controls by both methods (Table [5](#T5){ref-type="table"}).

###### 

*APOE*haplotype frequencies inferred by PHASE and HTR and the corresponding p-values showing the levels of difference between cases and controls.

  **Haplotype**             **Frequency**   ***p***-~**CS**~   ***p*-**~**HTR**~   
  ------------------------- --------------- ------------------ ------------------- -------
  TGTCGATCCTTC (Hap1)       0.296           0.194              0.001               0.001
  TGCCGATGCTTC (Hap2)       0.148           0.140              0.689               0.123
  CGCCAATCCTTC (Hap3)       0.074           0.068              0.704               0.216
  TGCCATTGCTTC (Hap4)       0.047           0.053              0.821               0.793
  TGTCGATCCCTC (Hap5)       0.050           0.040              0.438               0.203
  TGCCGACGCTTC (Hap6)       0.029           0.024              0.958               0.168
  TGCCATTCCTTC (Hap7)       0.035           0.025              0.521               0.086
  TGTTGATCCTTC (Hap8)       0.030           0.048              0.264               0.813
  TGCCGATGCCTC (Hap9)       0.021           0.034              0.309               0.647
  Rare Haplotypes (\<0.2)   0.271           0.374                                  
  Global Test                                                  0.019               0.036

***p***-~**CS**~: empirical p-values based on chi square test statistics, ***p***-~**HTR**~: empirical p-values based on haplotype trend regression test statistics.

To explore the haplotype association at a finer level, we conducted a \'sliding haplotype\' analysis to decompose Hap1, the most common and significantly associated haplotype. None of the other haplotypes showed significant association even with the sliding window analyses (data not shown), and they were consequently dropped from further analysis. A graphical representation of this analysis is presented in Figure [1](#F1){ref-type="fig"}. The uppermost circle in the figure, with the number \'1--12\', represents Hap1 inferred using all SNPs (SNPs 1 to12). Progressively smaller windows of this haplotype were formed at each level of the pyramid. These depict windows created with combinations of SNPs used in haplotype construction for that level (e.g., circle 1--11 represents the most common haplotype formed by SNPs 1 to 11, circle 2--12 represents the most common haplotype formed by SNPs 2 to 12, and so on). Haplotypes with significant associations are shown in yellow (*p*\~ 0.05--0.1), green (*p*\~ 0.01--0.05) and red (*p*\< 0.01). A trend of ascending significance is observed at the 5\' region. Marginal associations are also observed at the 3\' region, where SNPs encoding the isoformic ε2/ε3/ε4 variants are located (SNP10 and SNP12 together form the ε2/ε3/ε4 variants -- cytosine at both sites result in the ε4 isoform, thymine at the first site and cytosine at the second site form ε3, and thymine at both sites yield ε2).

![**Sliding Window Analysis of Hap1 (TGTCGATCCTTC)**. Each circle depicts the most common haplotype created by the SNPs indicated (e.g., circle 1--12 represents the most common haplotype formed by SNPs 1 to 12). Significance level of the most common haplotype is indicated by color: yellow (*p*\~ 0.05--0.1), green (*p*\~ 0.01--0.05) and red (*p*\< 0.01). Global significance for sliding window is 0.013.](1471-2350-8-49-1){#F1}

Genetic variation at the *ELN*locus
-----------------------------------

Genotype and allele frequencies of *ELN*SNPs among the cases with aneurysmal SAH and controls are presented in Table [6](#T6){ref-type="table"}. Genotypes were in HWE with the exception of SNP2 and SNP7. One marker *rs13229379*(SNP6) was found to be monomorphic in our population and was thus dropped from subsequent analysis. None of the SNPs were associated with SAH.

###### 

Distribution of genotypes and allele frequencies at the *ELN*gene in the Caucasian cases and controls

  **Locus**     **Genotype**   **Freq(q)**   **Cases vs. Controls (*p*-value)**                   
  ------------- -------------- ------------- ------------------------------------ ------- ------- -------
  SNP1          79             11            0                                    0.061   0.851   0.774
                141            16            1                                    0.057           
  SNP2          33             42            14                                   0.393   0.863   0.968
                56             71            26                                   0.402           
  SNP3          79             11            0                                    0.061   0.729   0.906
                138            20            1                                    0.069           
  SNP4          81             9             2                                    0.070   0.544   0.851
                144            22            4                                    0.088           
  SNP5          76             11            0                                    0.063   0.860   0.574
                142            18            2                                    0.067           
  SNP7          34             42            15                                   0.395   0.948   0.998
                63             76            27                                   0.391           
  SNP8          35             43            14                                   0.386   1       0.875
                63             84            23                                   0.382           
  SNP9          47             12            5                                    0.172   0.399   0.697
                83             24            14                                   0.215           
  SNP10         77             12            3                                    0.098   0.297   0.027
                126            42            1                                    0.130           
  Global Test                                                                             0.847   0.153

Using PHASE, we inferred haplotypes based on all 9 SNPs and did not observe significant associations (global *p*= 0.229 and 0.198; Table [7](#T7){ref-type="table"}). There was no association of haplotypes even after excluding the two markers (SNP2 and SNP7) that were not in HWE (data not shown). Further, the sliding window analysis showed no association between *ELN*and SAH.

###### 

*ELN*haplotype frequencies inferred by PHASE and HTR and the corresponding p-values showing the levels of difference between cases and controls.

  **Haplotype**     **Frequency**   ***p*-~**CS**~**   ***p*-~**HTR**~**   
  ----------------- --------------- ------------------ ------------------- -------
  GACCAGCGC(Hap1)   0.396           0.353              0.306               0.019
  GGCCAATGC(Hap2)   0.295           0.261              0.480               0.029
  GACCAGCAC(Hap3)   0.112           0.127              0.734               0.284
  GGCCAATGT(Hap4)   0.063           0.068              0.936               0.232
  TATTCGCAC(Hap5)   0.036           0.024              0.351               0.045
  Rare Haplotypes   0.097           0.167                                  
  Global Test                                          0.229               0.198

Discussion
==========

Although we did not observe significant association of the *APOE*variants and also could not confirm the association of *APOE*ε4 with SAH, we did find an association between SAH and the most common *APOE*haplotype, which occurred in nearly 1/3 of the SAH cases compared to 1/5 of controls. This haplotype included regulatory regions of the gene in the 5\' untranslated region. Since variations of the 5\' regulatory region are traditionally associated with decreased or increased expression of the gene, we hypothesize that regulation of *APOE*is the primary mechanism of association of this gene with SAH. We have not examined the 3\' untranslated region and our most distal 3\' SNP was within the last exon of the gene. Variations in the 3\' untranslated region are associated with post-transcriptional processing and we are unable to comment upon variations in these regions.

Our recent study in lobar ICH demonstrated that in addition to the association of *APOE*ε4 with lobar ICH, *APOE*haplotypes, which include non-coding variants in regulatory regions, mediate the risk of lobar ICH \[[@B11]\]. These findings underscore the importance of regulatory variants, in addition to coding sequences, in understanding the genetic basis of complex diseases.

Haplotypes have the advantage of providing information not only on the relationship of disease to a single polymorphism, but also on variants that are in linkage disequilibrium with the markers tested. The selection of large haplotypes may lead to \"over-partitioning\" in which haplotypes with very small frequencies may be spuriously associated with the phenotype in question. In our study, the most common haplotype was associated with the phenotype, making over-partitioning a less-likely confounder.

The primary function of APOE in lipid metabolism is to mediate the interaction of lipid particles with LDL and APOE receptors. The involvement of *APOE*polymorphisms in lipid metabolism, Alzheimer\'s disease, and a host of cardiovascular and cerebrovascular diseases imply pleiotropic effects of the gene \[[@B6]-[@B8]\]. Although outcome studies have implicated *APOE*ε4 as a risk allele for cognitive impairment following subacute phase of aneurysmal SAH \[[@B26]\] and a recent meta-analysis showed marginal association of ε4 carriers with SAH \[[@B27]\], the biological role of APOE in the etiology of SAH remains unclear. Based on epidemiologic studies showing association of lower cholesterol levels to hemorrhagic stroke including subarachnoid hemorrhage \[[@B28]-[@B30]\], it may be speculated that lipid metabolism involving APOE contributes to risk of SAH or its adverse outcomes.

A significant advantage of our study is the inclusion of polymorphisms other than those that code for *APOE*ε2 and *APOE*ε4. The overall haplotype spans a large region of the 5\' untranslated region and the exons of the *APOE*gene, which allows for an examination of the regulatory regions. The sliding window analysis provides a compelling indication of association, which emerges from the 5\' region of the gene. To our knowledge, no other study has examined any other SNPs of the *APOE*gene and risk of SAH.

The association of *ELN*with SAH has not been consistent. Using an affected sib-pair design, Onda *et al*. \[[@B14]\] first reported linkage of familial IA to chromosome 7q11 in Japanese families. The putative locus was later confirmed by linkage in a set of extended pedigrees from Utah \[[@B31]\]. However, two other linkage studies, from Japan and Finland, did not replicate these findings \[[@B32],[@B33]\]. A putative candidate gene, *ELN*, which maps to 7q11, raised the expectation of its association with IAs.

Although we did not find significant association either at allelic or haplotype levels, we do not to rule out the possible association of *ELN*with SAH. Differences in allele frequencies and haplotype structures among populations could influence association results. The allele frequencies for many SNPs in our population were different from those reported in the Japanese population \[[@B14]\]. Further, an associated polymorphism could be in LD with the functional variant and not be the functional variant by itself. Variation in LD pattern across populations, therefore, would be important in assessing association.

Case-control association designs should be viewed with caution because spurious association could be introduced by unrecognized population substructure. To guard against such false associations, we used a genomic control approach in which null markers distributed throughout the genome are used to adjust the association test statistics \[[@B24]\]. The adjustment is carried out by estimating a variance inflation factor, λ, from the distribution of the test statistics at the null loci. In the absence of substructure, λ is 1 and the genomic control approach is equivalent to a standard case-control test. A major strength of our study was that we used genomic control to evaluate and correct for any population substructure in our samples. The λ value obtained form the 30 null SNPs was 1.06. This clearly illustrates absence of any major population stratification in our samples, which suggests that our results of association or lack thereof remain valid.

Conclusion
==========

In conclusion, our study suggests a plausible role of the upstream regulatory region of *APOE*in the etiology of aneurysmal SAH. The complexity of the biological mechanisms underlying *ELN*in conjunction with genetic heterogeneity among ethnically diverse populations could influence our observed lack of association. Further studies with larger sample sizes and in additional ethnic groups are required to establish the likely involvement of *ELN*variants in SAH.
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